Breaking News, Collaborations & Alliances

B-MoGen & CytoSen Enter Research Collaboration

To develop the next generation of gene-modified natural killer cell (NK) therapies

B-MoGen Biotechnologies, Inc. and CytoSen Therapeutics have formed a research collaboration to develop the next generation of gene-modified Natural Killer Cell (NK) therapies.   B-MoGen will utilize its expertise in genetic design and its patented non-viral gene delivery platform in conjunction with CytoSen’s nanoparticle expansion platform to improve efficacy and reduce cost of NK cell therapeutics. The partnership looks to enable the creation and delivery of new NK cell therapies for ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters